RetinaCME

This activity is expired and is no longer available for CME credit.

EXPERT INTERVIEWCME

Update on Novel Oral Therapy for DME

Author(s)/Faculty: Tamie J. Chilcote, PhD
Release Date: 6/1/2012Expiration Date: 5/31/2015
Credit Type: CME / ParticipationNumber of Credits: 0
Content Type: Provider:
Administered systemically, ASP-440 is a selective, safe and efficacious inhibitor of diabetes-induced blood-retinal barrier breakdown. Oral dosing with the prodrug ASP-634 in rats & dogs resulted in large multiples of efficacious exposure of ASP-440, and these “super”-therapeutic doses were well-tolerated in both species. Based on these data, qd p.o. dosing at 70 mg in the clinic is projected to result in 24 h maintenance of >EC90 levels. ASP-634 is a novel oral clinical candidate for DME...